Synthetic biology specialist GRO Biosciences started exploring strategic alternatives about six months after raising a series ...

X-linked severe combined immunodeficiency disease (X-SCID) is a rare genetic disorder characterized by profound defects in ...

TRIMTECH Therapeutics’s incredible $31million seed funding haul will be deployed to develop treatments for severe ...

The team was able to reach protein yields at the pool stage that couldn’t be achieved previously with a random integration approach.

KRRO-110 is the first RNA editing development candidate from Korro’s proprietary OPERA TM platform and is currently being evaluated in the Phase 1/2a REWRITE clinical study for AATD. Dosing of the ...

Peptides designed by artificial intelligence restrict both drug-resistant bacteria and rapidly evolving viruses.

Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on ...

X-linked severe combined immunodeficiency disease (X-SCID) is a rare genetic disorder characterized by profound defects in T-cell, B-cell, and natural ...

Scientists dive into the genomes of whales, elephants, and other animal giants looking for new weapons in the fight against ...

Polyphosphate (polyP) exists in all life forms; however, its biological functions in metazoans are understudied. Here, we explored Drosophila as the first genetic model to explore polyP biology in ...

Sex differences in the risk factors, diagnosis, treatment, and outcomes of patients with cardiovascular disease have been ...